We have located links that may give you full text access.
Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 aptamer-mediated Targeted Drug Delivery into Cancer Cells.
Current Drug Delivery 2018 July 24
One of the major abundant proteins in nucleous is nucleolin that overexpressed on the cytoplasmic memberance of malignant and endothelial cells and makes it as a promising condidtae for targeted drug delivery. In this atudy, doxorubicin (Dox) as a chemotherapy drug was entrapped into the Poly lactic-co-glycolic acid (PLGA)-based nanoparticles (NPs). Then, the targeting ability of anti nucleolin AS1411 aptamer-targeted Dox-encapsulated PLGA-based NPs (AS1411-NPs) was investigated in high nucleolin-expressing C26 colon carcinoma and rat C6 glioma cell lines compared with low nucleolin-expressing mouse L929 cell line. We recently first assessed the existence of cell surface nucleolin of these three different cell lines by immunocytochemistry method. We found that large amount of nucleolin were localized on the cytoplasmic membrane of C26 and C6 cell lines, with very smaller amount on the surface of L929 cell line. As a result, more rapidly internalization of AS1411-NPs into the C26 and C6 cells compared with L929 cells was verified . We think that AS1411-NPs, as a ligand, first bind to nucleolin, as a receptor, and then the receptor-ligand complex is more efficiently incorporated into the high nucleolin-expressing cell lines through receptor-mediated endocytosis pathway.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app